Please login to the form below

Not currently logged in
Email:
Password:

GSK's Ellen Strahlman joins med tech firm BD

Will serve as the US company's chief medical officer

BD Dr Ellen StrahlmanNew Jersey-based medical technology company BD (Becton, Dickinson and Company) has appointed Dr Ellen Strahlman to the newly created role of chief medical officer and senior VP, research and development.

Dr Strahlman joins the firm from GlaxoSmithKline (GSK), which she joined in 2008, serving first as chief medical officer, and then senior medical advisor in the office of the CEO and global head of neglected tropical diseases.

Prior to her time with GSK, Dr Strahlman held executive leadership roles at Merck & Co, Novartis, Pfizer and Bausch & Lomb.

In her new role at BD Dr Strahlman will oversee the company's medical affairs and research and development functions.

"I am very pleased that Dr Strahlman will be joining BD at a time when we are strategically focused on driving growth through innovation and customer focus," said BD's CEO Vincent Forlenza. "She brings extensive experience as a senior physician and leader in the pharmaceutical and medical device industries, and her patient-centric approach aligns with our focus on providing innovative solutions to address the healthcare needs of customers and patients."

Headquartered in Franklin Lakes, New Jersey, BD develops, manufactures and sells medical devices, instrument systems and reagents.

14th March 2013

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics